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The E1 protein of bovine papillomavirus (BPV) is a site-specific DNA binding protein that recognizes an
18-bp inverted repeat element in the viral origin of replication. Sequence-specific DNA binding function maps
to the region from approximately amino acids 140 to 300, and isolated polypeptides containing this region have
been shown to retain origin binding in vitro. To investigate the sequence and structural characteristics which
contribute to sequence-specific binding, the primary sequence of this region was examined for conserved
features. The BPV E1 DNA binding domain (E1DBD) contains three major hydrophilic domains (HR1, amino
acids 179–191; HR2, amino acids 218 to 230; and HR3, amino acids 241 to 252), of which only HR1 and HR3
are conserved among papillomavirus E1 proteins. E1DBD proteins with lysine-to-alanine mutations in HR1
and HR3 were severely impaired for DNA binding function in vitro, while a lysine-to-alanine mutation in HR2
had a minimal effect on DNA binding. Mutation of adjacent threonine residues in HR1 (T187 and T188)
revealed that these two amino acids made drastically different contributions to DNA binding, with the T187
mutant being severely defective for origin binding whereas the T188 mutant was only mildly affected. Helical
wheel projections of HR1 predict that T187 is on the same helical face as the critical lysine residues whereas
T188 is on the opposing face, which is consistent with their respective contributions to DNA binding activity.
To examine E1 binding in vivo, a yeast one-hybrid system was developed. Both full-length E1 and the E1DBD
polypeptide were capable of specifically interacting with the E1 binding site in the context of the yeast genome,
and HR1 was also critical for this in vivo interaction. Overall, our results indicate that HR1 is essential for
origin binding by E1, and the features and properties of HR1 suggest that it may be part of a recognition
sequence that mediates specific E1-nucleotide contacts.
Bovine papillomavirus (BPV) replication requires only two
viral proteins, E1 and E2 (40), with the rest of the replication
machinery supplied by the host cell (27). Both the E1 and E2
proteins are site-specific DNA binding proteins which recog-
nize sequences in the viral origin of replication (1, 41, 42). The
E2 binding site (E2BS) is a 12-bp partial palindrome (1, 22),
while E1 binds to an 18-bp imperfect inverted repeat sequence
(18, 19, 34). In vitro, only the E1 protein is absolutely required,
indicating that the E2 protein does not supply a requisite
replication function (3, 5). Instead, E2 appears to act as an
auxiliary factor that interacts directly with E1 (24, 35, 44) and
increases binding site specificity (5, 32). Moreover, at low pro-
tein concentrations, E2-E1 complexes facilitate loading and
assembly of additional E1 molecules on the origin to form the
active initiation complex (30). Initial binding of E1 induces
distortion in the origin DNA that is a likely prelude to origin
unwinding, and this distortion of the origin DNA is also en-
hanced by E2 (13, 30). Ultimately, a hexameric E1 complex
with ATP-dependent helicase activity is assembled (11, 33),
though the precise steps in the formation of this hexamer are
undefined. E1 also interacts with several host cell proteins,
including DNA polymerase a and replication protein A (4, 14,
29), and presumably recruits these host replicative factors to
the viral initiation complex.
The origin binding function of E1 is central to its role in viral
genomic replication. Truncation studies of the 605-amino-acid
BPV E1 protein localized the DNA binding domain (DBD) of
E1 (the E1DBD) to approximately amino acids 140 to 300 (21,
31). Isolated polypeptides expressing this DBD region in the
absence of other E1 sequences retain origin-specific binding
activity (7, 21, 31, 39). Since the ATP binding site and helicase
activity map to the C-terminal portion of E1 and are not
present in the DBD, neither of these activities is required for
origin recognition (39). The E1DBD does retain the ability to
interact with E2 protein (21), and this interaction cooperatively
enhances origin binding (7). Clearly then, the E1DBD is a
functional subdomain with binding properties similar to those
of full-length E1 protein.
In contrast to the E2DBD, which has been crystallized and
studied in detail (15–17), little is known about the structure of
the E1DBD or the sequences which mediate origin binding. A
previous study identified a pair of conserved, heptad repeats of
hydrophobic residues from amino acids 249 to 282 (39). A
triple mutant with substitutions at two of the conserved hydro-
phobic residues failed to bind origin DNA, consistent with a
role for these elements in origin binding. However, the third
mutation in this triple mutant changed a conserved proline
located between the heptads to an alanine. The proline-to-
alanine substitution could likely have a significant effect on
protein folding in this region and makes interpretation of the
role of the heptad repeats uncertain. Two additional mutants
with basic residue-to-alanine substitutions in the region adja-
cent to the N-terminal side of the first heptad (amino acids 241
to 247) were both severely defective for origin binding, dem-
onstrating that this hydrophilic region was critical for E1-DNA
interaction. One additional mutation at a distal site, an argi-
nine 180-to-alanine substitution, reduced E1 DNA binding
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activity to less than 1% of the wild-type (WT) E1 level, though
this region was not investigated further (39). In the present
study, the hydrophilic region that includes E1 amino acid 180
was investigated in detail and was shown to be critical for
site-specific DNA binding both in vitro and in vivo. Features of
this region suggest that it may be part of a recognition se-
quence that mediates specific contact with nucleotides in the
E1BS.
MATERIALS AND METHODS
Plasmids and mutant construction. The DNA fragment encoding the WT
E1DBD region from amino acids 121 to 311 (E1121–311) was amplified under stan-
dard conditions from a cloned E1 gene, using Ultma DNA polymerase (Perkin-
Elmer) and primers E1AA121 (59-GAGCTGAATTCGCTAACCGTGTTCTT
ACGCCC-39) and E1AA311 (59-CGTCCGTCGACCGCGAATTTCTCGGTC
TGCAAGCT-39). The amplified product was ligated directly to pCRBLUNT
(Invitrogen) and transformed into TOP10 cells (Invitrogen). A recombinant
clone was identified, and the E1DBD fragment was excised from purified plas-
mid DNA by EcoRI digestion. The E1DBD fragment was ligated to pGEX-5X-1
DNA (Pharmacia Biotech) that had been linearized by EcoRI digestion and was
transformed into TOP10F9 (Invitrogen) cells. Clones were screened for the pres-
ence of the insert fragment, and a recombinant clone with the correctly oriented
fragment was identified. The entire sequence of the insert fragment was deter-
mined and found to be the correct, WT sequence and to be in frame with the
glutathione S-transferase (GST) coding region. This clone, designated pGEX-
E1DBD, was used for the production of all point mutants. Ten individual point
mutations were constructed in pGEX-E1DBD by site-directed mutagenesis using
mutagenic oligonucleotides and a QuikChange mutagenesis kit (Stratagene) as
specified by the manufacturer. Mutant clones were identified by direct DNA
sequencing of plasmid minipreparations; for each clone, only the desired muta-
tion was present in the E1DBD coding region.
For in vivo expression in yeast, E1 and the E1DBD were produced as fusions
with the GAL4 activation domain (AD), using the pGAD424 vector (Clontech).
For full-length E1, the 2,185-bp NruI-to-FspI fragment encompassing the E1 cod-
ing region was isolated from pdBPV.1 DNA by gel purification. BamHI linkers
were added to the fragment, and it was ligated to BamHI-digested pGAD424.
Two clones were identified with the insert in either the correct, forward orien-
tation [pGAD-E1(F)] or the reverse orientation [pGAD-E1(R)]. The vector-
insert junctions were sequenced to confirm the insert orientation and to
ensure that the forward clone could produce the AD-E1 fusion protein. For
the E1DBD, the E1121–311 fragment was excised from the above pCRBLUNT
clone by EcoRI digestion and ligated to EcoRI-digested pGAD424. Again, for-
ward (pGAD-E1DBD) and reverse [pGAD-E1DBD(R)] clones were identified
and confirmed by DNA sequencing. The expression of both the AD-E1 and the
AD-E1DBD proteins from these vectors in yeast was confirmed by Western
blotting (data not shown). pGAD53m (Clontech) expresses the AD-p53 protein
(mouse p53).
Purification of E1DBD proteins. For expression of WT and mutant E1DBD
proteins, the respective pGEX-E1DBD plasmids were transformed into Esche-
richia coli BL21. BL21 transformants were grown to mid-log phase at 37°C in
2XYT medium with ampicillin (50 mg/ml) and then induced by addition of
isopropyl-b-D-thiogalactopyranoside to 1 mM. After a 2-h induction, cultures
were packed in ice for 30 min and harvested by centrifugation (15 min at
10,000 3 g), and the pellets were frozen at 220°C. For lysis and extraction, the
cell pellets were thawed on ice, resuspended in a minimal volume of cold GST-C
buffer (50 mM Tris-HCl [pH 7.9], 250 mM NaCl, 5 mM EDTA, 5 mM dithio-
threitol [DTT], 10 mM phenylmethylsulfonyl fluoride [PMSF], 10% glycerol),
and incubated on ice for 60 to 120 min with lysozyme at a final concentration of
0.1 mg/ml. After the lysozyme digestion, the cell suspensions were subjected to
two rounds of passage through a prechilled French press cell at 16,000 lb/in2
followed by addition of NP-40 to 0.1%. Alternatively, some preparations were
lysed by resuspension of the original cell pellets in B-Per reagent (Pierce) fol-
lowed by lysozyme treatment. To further solubilize the proteins extracted by
either procedure, the extracts were sonicated twice for 15 s at maximum power
with a microtip in an Ultrasonics sonicator. The extracts were clarified by cen-
trifugation for 30 min at 20,000 3 g, and the supernatants were rotated overnight
at 4°C with glutathione-Sepharose beads (Pharmacia). Subsequently, the beads
were collected at 4°C by centrifugation for 5 min at 500 3 g and were washed
twice with 10 ml of cold GST-C, three times with 10 ml of cold GST-D (50 mM
Tris-HCl [pH 8.0], 200 mM NaCl, 5 mM EDTA, 5 mM DTT, 10 mM PMSF, 10%
glycerol), three times with 10 ml of cold GST-E (50 mM Tris-HCl [pH 8.0], 1.0
M NaCl, 5 mM EDTA, 5 mM DTT, 10 mM PMSF, 10% glycerol), and twice with
10 ml of cold GST-C. The washed beads were incubated for 10 min at room
temperature in 500 ml of GST-C with 10 mM reduced glutathione followed by
centrifugation for 1 min in a microcentrifuge. The supernatant containing the
GST-E1DBD fusions was collected, adjusted to a final concentration of 50%
glycerol, and stored at 220°C. Protein concentration was determined by a Brad-
ford assay (6), and purity was assessed by scanning sodium dodecyl sulfate
(SDS)-polyacrylamide gels with an IS1000 digital imaging system (Innotech
Corp.). For removal of the GST moiety, factor Xa cleavage was performed as
specified by Pharmacia. However, GST-E1DBD was found to be much more
stable in gel shift assays than the free E1DBD, and so the fusion proteins was
used for all the studies reported here. Comparison of the properties of GST-
E1DBD and free E1DBD will be reported elsewhere.
Probes. Two double-stranded oligonucleotide substrates, E1BS1-4 and E1BS0,
were prepared for the gel mobility shift assay. E1BS1-4 corresponds to 50 bp of
BPV sequence from nucleotides 7926 to 29 which includes the 18-bp E1BS and
the low-affinity E2BS12. E1BS0 is a 60-bp substrate corresponding to BPV
sequences 7916 to 29 with the 18-bp E1BS replaced by an unrelated 18-bp
palindromic sequence. Each of these double-stranded oligonucleotides was pre-
pared by incubating equal molar amounts of the following complementary single-
stranded oligonucleotides at 70°C for 5 min and then slow cooling to room
temperature: E1BS1-4U (59-TAATTGTTGTTAACAATAATCACACCATCA
CCGTTTTTTC-39) plus E1BS1-4L (59-TGATGGTGTGATTATTGTTAACA
ACAATTATTCACTGGGA-39); and E1BS0U (59-TATCACACCGACTGTGA
GCACACACCATCACCGTTTTTTC-39) plus E1BS0L (59-TGCTCACAGTCG
GTGTGATATTCACTGGGAAAAAATACAT-39). The hybridized oligonucle-
otides have 59 overhangs which were subsequently radiolabeled and made blunt
by incubating 1 pmol of substrate in 12.5 mM Tris-HCl (pH 7.2), 5 mM MgCl2,
10 mM DTT, 32 mM each dATP, dGTP, and dTTP, 0.33 mM [a-32P]dCTP, and
2 U of Klenow polymerase for 60 min at 25°C followed by addition of 32 mM
dCTP and incubation for another 10 min. Full-length, radiolabeled, double-
stranded substrates were purified by excision and elution from 12% nondena-
turing Tris-borate-EDTA gels into gel shift assay buffer (20 mM potassium
phosphate [pH 7.0], 100 mM NaCl, 1 mM EDTA, 0.1% NP-40, 10% glycerol).
Gel mobility shift assay. Mobility shift assays were performed basically as
described by Chen and Stenlund (7). Purified WT or mutant GST-E1DBD
proteins were incubated with 2.5 fmol of radiolabeled substrate and 20 ng of
pUC18 DNA in 10-ml reaction mixtures consisting of gel shift assay buffer
supplemented to a final concentration of 5 mM DTT and 0.07% bovine serum
albumin. Samples were incubated for 30 min at 25°C and then loaded onto 8%
polyacrylamide gels in 0.53 Tris-borate-EDTA buffer. The 103 Tris-borate
stock used for both the gel and the tank buffer was adjusted to pH 7.5, as this pH
provided better resolution of protein-DNA complexes. Gels were electropho-
resed at 100 V for 4 to 5 h. Dried gels were visualized and quantitated with a
Molecular Dynamics PhosphorImager.
Yeast one-hybrid system. Plasmid p53BLUE (Clontech) contains three tan-
dem copies of the p53 binding site (p53BS) inserted into a minimal yeast pro-
moter (PCYC1) upstream of the lacZ gene in plasmid pLacZi. A similar E1
reporter plasmid was constructed by cloning a double-stranded oligonucleotide
consisting of three tandem copies of the 18-bp E1BS into the PCYC1 region of
pLacZi. The sequence of the resultant recombinant, designated pLacZi-E1BST,
was confirmed by DNA sequencing. Purified p53BLUE and pLacZi-E1BST
DNAs were linearized by NcoI digestion to promote vector integration and
transfected into Saccharomyces cerevisiae YM4271 by the polyethylene glycol-
lithium acetate procedure (12). Transformants were selected on minimal me-
dium lacking uracil and were passaged several times on this medium to eliminate
cells harboring unintegrated vector. The resulting yeast reporter strains contain-
ing either the integrated p53BS promoter-lacZ gene or the E1BST promoter-
lacZ gene were designated p53BS-LACZ and E1BST-LACZ, respectively. Pu-
rified plasmid DNAs encoding the various GAL4 AD fusions were transfected
into both of the reporter strains, and transformants were isolated on minimal
medium lacking uracil and leucine.
Western blots. Whole-cell extracts were prepared from the yeast transfor-
mants by freeze-thawing cell pellets three times and then boiling them for 10 min
in cracking buffer (40 mM Tris-HCl [pH 6.8], 0.1 mM EDTA, 8 M urea, 5% SDS,
0.04% bromophenol blue, 0.88% b-mercaptoethanol, 0.077% PMSF). Equiva-
lent amounts of protein from each sample were electrophoresed on a 12% poly-
acrylamide gel, and the proteins were electrophoretically transferred to a Protran
nitrocellulose membrane (Schleicher & Schuell) as previously described (21).
The blots were probed with a 1/1,000 dilution of anti-GAL4 AD (Upstate Bio-
technology) and visualized by enhanced chemiluminescence with Super Signal
(Pierce).
b-Galactosidase assays. Two procedure were used for assessing the interac-
tion of AD fusion protein with the E1BST or p53 promoter in the yeast reporter
strains, a colony lift filter assay, and a liquid culture CPRG (chlorophenol red-
b-D-galactopyranoside) assay. Both assays were performed as described in the
Clontech Yeast Protocols Handbook. A brief description of each assay follows.
(i) Colony-lift filter assay. Transformants were inoculated onto an appropriate
selective medium and grown for 2 to 3 days at 30°C until colonies were 1 to 2 mm
in diameter. Colonies were replica lifted onto Whatman filter paper and lysed by
freezing in liquid nitrogen followed by a thaw at room temperature. Subsequently
the filter was wetted by incubation on top of a second filter soaked in Z buffer (50
mM sodium phosphate [pH 7.0], 10 mM KCl, 1 mM MgSO4, 0.27% b-mercap-
toethanol) with 330 mg of X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopy-
ranoside) per ml. Development of blue color was monitored visually, and the
filter was photographed with an IS1000 digital imaging system (Innotech).
(ii) Liquid culture CRPG assay. Overnight cultures were grown in the appro-
priate selective medium for each transformant, and the optical density at 600 nm
was recorded for later normalization. Cultures (1.5 ml) were harvested by cen-
trifugation in microcentrifuge tubes, washed one time with buffer 1 (10 mM










HEPES [pH 7.3], 150 mM NaCl, 0.065% L-aspartate, 1% bovine serum albumin,
0.05% Tween 20), and resuspended in 300 ml of buffer 1. Cells were lysed by
three cycles of alternating between liquid nitrogen and a 37°C water bath.
Aliquots of 100 ml of lysed cells were mixed with 700 ml of buffer 1 containing
2.23 mM CPRG and vortexed thoroughly. Samples were incubated at room
temperature until visible color formation was observed or for up to 3 h. After
color formation, or at 3 h if no color was observed, the reactions were stopped
by addition of 500 ml of 3 mM ZnCl2. Cell debris was removed by centrifugation
for 1 min in a microcentrifuge, the optical density at 578 nm of the supernatants
was read for each sample, and the b-galactosidase units were calculated. All
samples were assayed in triplicate, and the values reported are the average.
RESULTS
Conservation of hydrophilic domains in the E1DBD. We
previously showed that the origin-specific DNA binding activ-
ity of the BPV E1 protein resides in the E1121–311 fragment and
that this isolated polypeptide retained site-specific recognition
function (21). To initiate a functional study of the E1DBD, the
primary sequence was examined for physical features. Hydrop-
athy plots of the BPV E1DBD were prepared by using six
different algorithms. All six plots were very similar (data not
shown) and revealed three subregions with a high degree of
intrinsic hydrophilicity, possibly reflecting accessible sequences
capable of interacting with origin nucleotides. In the Kyte-
Doolittle plot shown in Fig. 1A, the hydrophilic regions are
designated HR1, HR2, and HR3. Given the cross-species func-
tional conservation of E1 proteins (2, 8, 38) and the sequence
conservation of the E1BS among different papillomaviruses
(18), it was likely that subregions of the E1DBD critical for
origin interaction would show some conservation of overall
properties and specific primary amino acid sequence. Conse-
quently, similar examination of hydropathy plots was con-
ducted for the predicted DBDs of eight human papillomavirus
(HPV) E1 proteins (Table 1). All eight HPV E1 proteins had
significant hydrophilic character in the regions corresponding
to HR1 and HR3 of BPV E1, while only three of the eight were
FIG. 1. Sequence features of the E1DBD. (A) Kyte-Doolittle hydropathy plot of the BPV E1121–311 protein. There are three major hydrophilic peaks, designated
HR1, HR2, and HR3. HR1 and HR3 are conserved among papillomavirus E1 proteins, and HR2 is nonconserved. Mutations previously shown to impair E1 DNA
binding (39) are marked with asterisks. Numbered vertical arrows indicate the amino acid number of lysine residues mutated to alanine in this study. (B) Amino acid
conservation and the relative hydrophilicity of the flanking sequence regions for each lysine analyzed.




Amino acid rangeb Avg hydrophilicityc
HR1 HR2 HR3 HR1 HR2 HR3
BPV-1 179–191 218–230 241–252 21.43 20.91 20.75
HPV-1a 185–197 224–236 244–255 21.02 20.32 0.56
HPV-8 181–193 219–230 235–246 20.81 1.18 20.85
HPV-41 191–203 228–240 250–261 21.15 20.02 20.73
HPV-47 182–194 221–232 238–249 20.94 0.67 20.64
HPV-11 224–236 263–275 283–294 20.63 0.58 20.36
HPV-16 223–235 262–274 285–296 20.66 21.44 21.35
HPV-18 230–242 269–281 288–299 20.98 0.81 20.36
HPV-33 216–228 255–267 275–286 20.83 0.60 20.31
a Representative papillomaviruses from both the cutaneous (HPV-1a, -8, -41,
and -47) and mucosal (HPV11, -16, -18, and -33) types were examined.
b Amino acid numbers for each papillomavirus E1 protein in the regions
corresponding to HR1, HR2, and HR3 of BPV E1.
c The Kyte-Doolittle hydrophilicity values for each amino acid position within
the indicated region were summed, and the average for each region is reported.










hydrophilic in the region corresponding to HR2. This conser-
vation of HR1 and HR3 implicates them both as potentially
important for E1 DNA function, while HR2 may be of lesser or
no significance. Consistent with this prediction, amino acids
within HR3 have already been shown to be critical for origin
binding by BPV E1 (39). HR1 has not been thoroughly inves-
tigated, although mutation of amino acid 180 at the N-terminal
boundary of HR1 dramatically reduced the origin binding abil-
ity of E1 in an earlier study (39).
Charge-to-alanine mutations identify critical amino acids
for E1DBD origin recognition function. To investigate the con-
tribution of HR1 to origin binding, lysine-to-alanine mutations
were constructed at conserved residues 183 and 186 in the
context of the isolated E1DBD polypeptide (Fig. 1B). Addi-
tional lysine-to-alanine mutations were created elsewhere in
the DBD at both conserved and nonconserved residues located
in sequence contexts of varying hydrophilicity. Each mutant
E1DBD protein was expressed as a GST fusion and affinity
purified to greater than 90% homogeneity (Fig. 2). The puri-
fied proteins were assayed for in vitro DNA binding activity
using a gel shift assay with short (50- or 60-bp) double-stranded
oligonucleotides as the substrates (Fig. 3). Oligonucleotides of
this length were previously shown to be sufficient for efficient
binding of E1 protein (18). The binding test substrate con-
tained the authentic BPV origin sequence consisting of the
AT-rich element, the E1BS, and the low-affinity E2BS12, while
FIG. 2. Analysis of purified WT and mutant GST-E1DBD proteins. Each
protein was expressed and purified on glutathione-Sepharose as described in
Materials and Methods; 100 ng of each protein was electrophoresed on an
SDS–10% polyacrylamide gel and then stained with Coomassie blue. The mo-
lecular masses of the marker proteins (lane M) are indicated in kilodaltons.
FIG. 3. DNA binding by WT and mutant E1DBD proteins. (A) Gel mobility shift assays of WT and mutant E1DBD proteins. Each protein was assayed at 37.5 and
150 ng. Lanes marked 2 had no E1DBD added to the reaction and show the input unbound substrate; lanes 1, 2, 11, and 12 contain reactions using the E1BS0 substrate
that lacks the E1BS, while all the other lanes have the complete origin substrate, E1BS1-4. (B) Quantitation of the binding results from panel A. The total amount
of bound oligonucleotide was determined for the 37.5- and 150-ng samples with a PhosphorImager. The value for WT E1DBD was set as 100%, and the others are
expressed relative to this value. Shown are the average results for the 150-ng samples from two experiments; error bars for the WT and 279A samples are too small
to be seen. The relative results were similar with the 37.5-ng samples (not shown).










the control substrate was identical except that the 18-bp E1BS
was replaced with an unrelated palindromic sequence.
At low concentrations of WT E1DBD, a single predominant
E1-DNA complex was observed with the origin substrate, while
at higher concentrations additional retarded complexes were
formed (Fig. 3, lanes 3, 4, 14, and 15). Mixing studies with
GST-E1DBD and a GST-E11–311 protein indicate that the pre-
dominant complex is a monomer of GST-E1DBD bound to
the substrate (C. Bazaldua-Hernandez and V. G. Wilson, un-
published results). This suggests that the more slowly migrating
complexes represent bound dimers and trimers of GST-
E1DBD; more detailed studies of the various WT E1DBD-
DNA complexes will be presented elsewhere. Under the assay
conditions used, there was no binding of WT E1DBD to the
control substrate (lanes 1, 2, and 12), demonstrating the spec-
ificity of the E1DBD-DNA complexes. Both the K183A and
K186A mutations in HR1 severely impaired origin binding
function to less than 5% of WT activity (lanes 7 to 10). The
K241A mutation in HR3 showed a similar reduction in DNA
binding (lanes 18 and 19), and its impairment was comparable
to that previously observed by Thorner et al. for a K241A/
R243A double mutant in the context of full-length E1 (39). In
contrast, a lysine-to-alanine mutation at position 222 in the
nonconserved HR2 had only a minimal effect on overall DNA
binding activity. The K222A mutant exhibited the same qual-
itative pattern of protein-DNA complexes and showed only a
10 to 20% reduction in amount of complexes formed at the
higher protein concentration (lanes 16 and 17). Similarly, non-
conserved lysine K157 appeared to make no significant contri-
bution to origin binding since the K157A mutant E1DBD
protein bound the origin substrate as well as the WT protein,
both qualitatively and quantitatively (lanes 5 and 6). Interest-
ingly, E1DBD proteins with alanine mutations at conserved
lysines 267 or 279 showed only modest reduction in binding
activity (lanes 20 to 23), suggesting that these lysines may be
conserved for some function(s) besides direct DNA binding.
Overall, the in vitro binding results are consistent with HR1
and HR3 being critical motifs for E1 DNA binding activity.
Both full-length E1 and the E1DBD exhibit site-specific
DNA binding activity in vivo. The above results, as well as
previously published reports of E1 DNA binding, were all in
vitro studies of E1-DNA interactions. Little is known about the
interaction of the E1 protein with its binding site in an in vivo
context where the host cell milieu might influence E1 binding
activity. In vivo transient replication assays are sensitive to E1
binding ability but are not useful for direct comparison of
mutant binding activities since each mutation may also affect
other E1 replication functions. Consequently, to evaluate the
DNA binding activity of E1 protein in vivo more directly, we
developed a yeast one-hybrid assay. An E1 reporter strain,
designated E1BST-LACZ, was constructed with three tandem
copies of the 18-bp E1BS integrated into the yeast genome
within a minimal promoter sequence adjacent to a lacZ gene.
The control strain had a similar organization except that it
contained three copies of a p53BS rather than the E1BS and
was designated p53BS-LACZ. Both the reporter and control
strains were transfected with a series of plasmids expressing
various fusions between the GAL4 AD and either p53 or E1.
Transformants were isolated and replated on selective me-
dium, and the colonies were assayed for b-galactosidase activ-
ity by an X-Gal overlay procedure (Fig. 4). Both the E1BST-
LACZ and the p53BS-LACZ reporter strains expressing the
AD protein alone produced no detectable b-galactosidase, and
the colonies remained white even after overnight incubation
with X-Gal. The absence of b-galactosidase activity demon-
strated the extremely low endogenous expression from either
the E1BS promoter or the p53BS promoter and confirmed that
the AD alone showed no interaction with these promoter el-
ements.
In contrast to the AD alone, expression of the AD-p53
fusion and the AD-E1 fusion resulted in b-galactosidase pro-
duction in their respective binding site promoter strains. In
each case, dark blue color was observed within 1 h after incu-
bation with X-Gal. Neither fusion protein activated transcrip-
tion from the promoter lacking its cognate binding site, dem-
onstrating the specificity of these interactions. Furthermore, a
clone with the E1 gene in the reverse orientation failed to
activate transcription of either strain. This control confirmed
that the production of b-galactosidase seen with the AD-E1
fusion in the E1BST-LACZ strain required expression of the
E1 protein and was not due to some intrinsic property of the
expression vector sequences. Therefore, full-length E1 protein
is capable of specifically recognizing and binding to its binding
site in vivo in a yeast genomic background.
Since the full-length E1 protein showed specific in vivo bind-
ing activity, we tested whether the in vitro-defined DBD also
functioned in vivo. Like full-length E1, the AD-E1DBD fusion
specifically activated the E1BS-containing promoter but not
the p53BS promoter. Again, the reverse E1DBD clone failed
to activate either promoter. These results demonstrate that
amino acids 121 to 311 constitute a functional DBD capable of
specific in vivo recognition of the E1BS in the nuclear envi-
ronment. Interestingly, the E1DBD fusion was two- to three-
fold more active than the full-length E1 fusion in quantitative
b-galactosidase assays when data were normalized for fusion
protein expression levels (Bazaldua-Hernandez and Wilson,
unpublished results). This discrepancy could be the result of
trivial differences relating to folding or aggregation of the
FIG. 4. Yeast one-hybrid analysis of E1 DNA binding in vivo. Six GAL4AD
vectors expressing the AD alone or as a fusion with E1 [AD-E1(F), forward
clone; AD-E1(R), reverse clone], E1DBD [AD-E1DBD, forward clone; AD-
E1DBD(R), reverse clone], or p53 (AD-p53) were transfected into both the
E1BST-LACZ and p53BS-LACZ reporter strains. Individual transformants were
regrown on selective medium for 48 h and photographed with an IS1000 digital
imaging system (Colonies). The colonies themselves are actually white but ap-
pear darkish in the photograph. The colonies were replica transferred to filter
paper and tested for b-galactosidase activity with the colony lift filter assay as
described in Materials and Methods. The results of the b-galactosidase (b-gal)
assay are shown in the right two columns. Three colonies turned blue; these three
b-galactosidase-positive clones appear dark in the photo, while the white colo-
nies are not visible.










individual fusion proteins, or it might reflect an actual differ-
ence in activity due to biologically relevant processes such as
posttranslational modification. Further studies are in progress
to address the basis of our observation.
HR1 is critical for E1 DNA binding in vivo. Our in vitro
results with the E1DBD identified sequences in HR1 as critical
for E1-E1BS interaction. To examine the importance of this
region in vivo, the E1 K183A mutation was constructed in the
AD-E1DBD fusion for analysis in the one-hybrid system. As a
control, the K157A mutation, which had no effect on E1DBD
binding in vitro, was also transferred to the AD-E1DBD pro-
tein. Each mutant vector was transfected into both the E1BST-
LACZ and p53BS-LACZ strains, and 10 transformants from
each set were tested for b-galactosidase activity (Fig. 5A). All
10 transformants expressing AD-E1DBDK157A in the E1BST-
LACZ strain were b-galactosidase positive within 1 h; how-
ever, the AD-E1DBDK183A transformants remained white for
up to 8 h. After overnight incubation, the AD-E1DBDK183A
transformants exhibited faint blue color indicative of very
low level of b-galactosidase expression. Neither the AD-
E1DBDK157A nor the AD-E1DBDK183A transformants pro-
duced any detectable b-galactosidase activity in the p53BS-
LACZ strain, even after overnight incubation.
To more accurately compare the binding activities of the
K157A and K183A mutants, individual transformants were
grown in liquid culture and tested by a quantitative spectro-
photometric assay for b-galactosidase (Fig. 5B). Consistent
with both the plate assay and in vitro results, the K157A mu-
tant exhibited WT levels of b-galactosidase activity whereas
the level for the K183A mutant was reduced approximately
25-fold. No activity was detected with either mutant in the
p53BS-LACZ strain. The dramatically decreased binding ac-
tivity of the K183A mutant was not due to reduced expression
of the AD-E1DBD protein, as comparable amounts of the
fusions were observed by Western blotting in each of the four
transformants tested (Fig. 5C).
Orientation of the critical residues in HR1. The in vitro and
in vivo studies implicated HR1 as critical for DNA binding
activity of the BPV E1 protein. Projection of this region of E1
in a helical wheel format revealed an extremely hydrophilic
face which included all three of the residues whose mutation
abolished site-specific DNA binding: K180, K183, and K186
(Fig. 6). All three of these residues also are highly conserved in
E1 proteins among all papillomavirus groups, which supports a
critical functional role for this region. To further evaluate the
possible importance of this hydrophilic surface, additional mu-
tations were constructed. In the helical projection, threonine
187 lies on the hydrophilic face between critical residues R180
and K183, while threonine 188 is on the opposing half of the
helix. Thus, these two threonines which are adjacent in the
primary sequence are potentially located in very different en-
vironments with respect to possible DNA interaction. Support-
ing this possible functional difference, threonine at the position
corresponding to amino acid 187 in BPV E1 is absolutely
conserved whereas the 188 position is variable. However, there
are also conserved residues on the opposing face such as tryp-
tophan 192 and aspartic acid 185. To determine if a conserved
residue on this opposing face contributes significantly to DNA
binding activity, D185 was chosen for analysis since it is located
within the short stretch of critical primary sequence defined by
inactivating mutations (residues 180 to 186) yet projects to the
opposite face from these essential residues. Each of these three
residues, D185, T187, and T188, was mutated to an alanine in
the context of the E1DBD protein and then tested for in vitro
DNA binding activity (Fig. 7). Mutation of T187 completely
abolished DNA binding activity (,2% of the WT level), while
the nonconserved T188 mutation showed only a modest 20 to
40% reduction in origin binding. The D185A mutant was more
impaired than the T188 mutant but still exhibited 30 to 50% of
WT binding activity in repeated trials, and it was substantially
FIG. 5. In vivo activity of E1DBD mutants. (A) The E1 K157A and K183A
mutations were constructed in the AD-E1DBD background and transfected into
both the E1BST-LACZ and p53BS-LACZ reporter strains. Ten transformants from
each transfection were picked onto a grid plate (1-10, E1DBDK157A/E1BST-
LACZ; 11-20, E1DBDK157A/p53BS-LACZ; 21-30, E1DBDK183A/E1BST-LACZ;
31-40, E1DBDK183A/p53BS-LACZ) and assayed for b-galactosidase activity as in
Fig. 4. b-Galactosidase-positive, blue colonies (1-10) appear dark in this photo,
while the negative, white colonies (11-40) are not visible. (B) Quantitative b-ga-
lactosidase assay for representative transformants from panel A. The reporter
strains, E1BST-LACZ (designated E1BST) and p53BS-LACZ (designated p53BS),
expressing either AD-E1DBDK175A (K157A bars), AD-E1DBDK183A (K183A
bars), or the WT AD-E1DBD fusion (WT bars) were grown in liquid medium
and assayed for b-galactosidase activity as described in Materials and Methods.
(C) Western blot of the mutant transformants used in panel B. Cell extracts were
prepared, electrophoresed on an SDS–10% polyacrylamide gel, transferred, and
probed with an anti-AD serum. Lane 1 is a control extract from the E1BST-
LACZ strain without an AD expression vector; lanes 2 to 5 are the four trans-
formants of the two reporter strains with the E1DBD K157A or K183A muta-
tions as indicated. The arrow marks the AD-E1DBD fusion protein.










more active than the T187A mutant. These result are consis-
tent with the helical wheel prediction that the amino acids
critical for DNA binding in HR1 are located on a common
surface. The greater impact of the D185A mutation on binding
than of the T188A mutation may reflect the effect of charge
loss on overall structure in this region.
DISCUSSION
Papillomavirus E1 proteins are absolutely critical for initia-
tion of viral DNA replication, serving as both origin recogni-
tion factors and helicases (36, 39, 41, 42, 44, 45). While several
functional domains of E1 proteins have been defined (21, 25,
45), little is known about the actual three-dimensional struc-
ture of these proteins. Definition of the primary, secondary,
and tertiary structures required for various biochemical activ-
ities and molecular interactions will be essential for under-
standing how initiation complexes assemble on the viral origin.
Previously we showed that the DBD of BPV E1 is functional as
an isolated polypeptide of approximately 190 amino acids (21).
The E1DBD protein specifically recognizes the E1BS se-
quence in origin DNA fragments in vitro and also interacts
with the viral E2 protein (21). A subsequent study with a
slightly smaller E1DBD confirmed these properties and also
demonstrated cooperative origin binding between the E1DBD
and both full-length E2 and the E2DBD (7). The ability of the
isolated E1DBD to function in origin recognition and E2
interaction in the same fashion as full-length E1 enables
studies of E1-DNA interactions to be performed with this
smaller molecule that is more easily expressed, purified, and
analyzed.
In this study we examined predicted HRs of the E1DBD as
potential molecular surface tracts that might be directly in-
volved in DNA contact. The BPV E1DBD has three major
HRs, two of which, HR1 (BPV E1 amino acids 179 to 191) and
HR3 (amino acids 241 to 252), are well conserved among
papillomavirus E1 proteins. A previous mutational analysis
showed that conserved basic residues in HR3 are critical for E1
DNA binding activity (39), and we now demonstrate a similar
requirement for basic residues in HR1. In contrast, mutation
of a lysine residue in nonconserved HR2 caused only a small
decrease in origin binding activity, indicating that this hydro-
philic region is not as important for E1-DNA interaction. In-
spection of the HR1 sequence suggested that all three basic
residues known to be required for DNA binding could be
physically juxtaposed on the helical face. Consistent with this
prediction, mutation of T187 located on the same predicted
face as the basic residues produced an E1DBD protein se-
verely impaired for sequence-specific DNA binding in vitro. In
contrast, the adjacent T188 residue is predicted to be on the
opposing helical face, and its mutation had a relatively small
effect on DNA binding activity. Likewise, mutation of a con-
served residue on the same face as T188, D185, also resulted in
a protein that was substantially more active than the T187A
mutant. From these results, residue D185 is clearly not as
critical for DNA binding as those on the hydrophilic helical
face, though its high conservation suggests that it may function
in some other E1 activity. While the actual secondary structure
of HR1 is unknown, these mutational results support the ex-
istence of a hydrophilic face including at least four residues
critical for E1 DNA binding function: R180, K183, K186, and
T187.
In the absence of crystallographic or spectroscopic data on
the structure of E1, it is useful to compare E1 with the simian
virus 40 (SV40) large T antigen, with which it shares sequence
and functional homology (9, 26). Even though these two pro-
teins recognize completely different nucleotide sequences, there
are some intriguing parallels to their DBDs (Fig. 8). First, their
DBDs are of similar size, and each comprises a relatively small
portion of the full-length protein: approximately 130 amino
acids out of 708 for SV40 T antigen (20, 28) versus approxi-
mately 170 out of 605 for E1 (7, 21). (Note that the boundaries
for the E1DBD might actually be even slightly smaller, as they
have not been precisely defined.) Furthermore, the two DBDs
are located in similar positions in the primary sequences, both
beginning approximately 130 to 140 amino acids from the N
terminus. Mutational analysis of T antigen defined two sets of
critical amino acids for specific origin DNA binding, regions A
FIG. 6. Helical projection and conservation of amino acids in HR1. Amino acids 176 to 193 of BPV E1 protein are displayed on the left in a helical wheel projection.
The horizontal line divides the helix into two halves: an upper, highly basic, hydrophilic face, and a lower, more hydrophobic face. Lysine and arginine residues shown
to be critical for DNA binding activity are marked with asterisks. The arrows indicate the two consecutive threonines and the aspartic acid that are functionally evaluated
in Fig. 7. On the right is a comparison of the BPV E1 sequence from amino acids 176 to 193 aligned with the corresponding regions from the papillomavirus groups
A to E and unclassified. The sequence shown for each papillomavirus group is the consensus sequence for these BPV E1-equivalent regions. Numbered residues refer
to the BPV E1 amino acid number. Boxes indicate residues that are absolutely conserved with the exception of positions 183 and 185, which diverge in the group C
and group B sequences, respectively.










(residues 152 to 155) and B2 (residues 203 to 207) (37, 43).
Recent solution nuclear magnetic resonance studies on the
isolated T-antigen DBD indicate that the A and B2 elements
form a juxtaposed surface region that is the likely penta-
nucleotide contact site (23). Our present results, combined
with those of Thorner et al. (39), identify two separate regions
necessary for E1 binding activity, HR1 and HR3. HR1 and
HR3 are separated by 49 intervening residues, compared to
47 amino acids between T-antigen regions A and B2. These
similarities in organization of the DBDs for T antigen and
E1 suggest that they could possess related three-dimensional
structures. As the T-antigen DBD structure shares folding
features with the DBDs of papillomavirus E2 proteins and the
Epstein-Barr virus nuclear antigen 1 (10, 23), the E1DBD may
also be part of this superfamily.
In addition to the in vitro DNA binding studies, a yeast
one-hybrid system was developed to assay E1-DNA interac-
tions in vivo. The full-length E1 protein exhibited site-specific
DNA binding activity, which is the first direct demonstration
that the minimal 18-bp E1BS sequence is sufficient to mediate
E1-DNA interaction in the environment of the host cell nu-
cleus. Given the relatively modest sequence specificity of E1
protein in vitro (32), the ability of E1 to locate and specifically
bind the E1BS in the background of the yeast genome, and in
the absence of E2 protein, was initially somewhat surprising.
While the yeast genome is approximately 250-fold smaller than
mammalian genomes, the absolute ratio of total nuclear DNA
to E1BS DNA in the yeast strain is still at least a 1,000-fold
larger than the ratio of competitor DNA to E1BS DNA that
will prevent E1 binding in vitro (32). One factor that may
facilitate the in vivo binding of E1 is that the E1BS sequence in
the E1BST-LACZ reporter strain is a tandem triplet which
should provide a higher local concentration of the target se-
quences. A second factor is that much of the vast excess of
nuclear DNA may be inaccessible due to association with his-
tones and host cell regulatory proteins, while the promoter
region would naturally be more available. Because of this un-
certainty in the actual amount of functional competitor, it is
difficult to make quantitative comparisons between the in vivo
and in vitro binding results.
Like the full-length E1 protein, the E1DBD specifically in-
teracted with the E1BS in the one-hybrid system. These results
confirmed that this in vitro-defined DBD domain is also stable
and functional in vivo. The activity of the E1DBD in the yeast
system allowed us to examine the role of HR1 in vivo. Muta-
tion of K183 in HR1 severely impaired binding by the AD-
E1DBD fusion, demonstrating that this region is as essential in
vivo as it was in vitro. Furthermore, mutations in HR1 are the
most frequently obtained clones when the one-hybrid system is
used to screen for randomly generated mutants lacking DNA
binding activity (M. West, unpublished data). In contrast to the
K183A mutant, the K157A mutant was equivalent to WT both
in vitro and in vivo. The concordance between the in vitro and
in vivo binding activities indicates that the in vitro defects in
binding are not simply the result of reduced stability of the
mutant proteins during extraction and purification and instead
represent intrinsic properties of the proteins. Overall, our re-
sults strongly implicate HR1 as a critical element for origin-
specific binding by E1 protein and, by analogy with SV40 T
antigen, suggest that the HR1 comprises at least part of the
recognition sequence.
FIG. 7. DNA binding activity of aspartic acid 185, threonine 187, and thre-
onine 188 mutants. (A) D185, T187A, and T188A mutations were constructed
into the E1DBD protein. Purified mutant and WT proteins were tested for origin
binding activity by the mobility shift assay described in the legend to Fig. 3 with
the complete origin oligonucleotide, E1BS1-4, as the substrate. The series of
three lanes for each sample contained 20, 40, and 80 ng of protein. The lane
marked 2 lacked E1DBD in the binding reaction. (B) The total of bound
complexes for each sample in panel A was quantitated with a PhosphorImager
and plotted as a function of protein amount.
FIG. 8. Organization of the DBD regions of SV40 large T antigen and BPV E1. The DBD domains of each protein are shaded, and the ATPase regions are striped.
Within the DBDs, the open rectangles labeled A and B2 for T antigen and HR1 and HR2 for E1 indicate the locations of sequence regions critical for DNA binding
activity (see text for details). The double-headed arrows between the open rectangles represent the similar spacing of approximately 50 amino acids in both proteins.
Numbers refer to amino acids of each protein.
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